• Twitter
  • Facebook
  • LinkedIn
Biweekly newsletter of the International Cytokine & Interferon Society

Biweekly newsletter of the International Cytokine & Interferon Society

Signals+ Editors: Daniella Schwartz & Di Yu (Editors in Chief), Saurabh Chattopadhyay, Zhian Chen, Mohamed Saad & Maialen Sebastian-delaCruz
  • Subscribe
  • Archives
    • Archives (Oct. 2023 and before)
      • Signals+ October 2022 PDF
      • Signals+ April 2021 PDF
      • Signals+ April 2022 PDF
  • Awards
  • Annual Meeting
  • Member News
    • Member Highlights
    • Members in the News
    • Members on the Move
    • New Member Mini-Bios
    • Articles of Interest
    • Reviews of Interest
  • Society News
    • President’s Letter
    • Featured Article!
  • Industry News
    • Industry Partner News
    • Other Meetings
    • Clinical Trials
HomeSignals+ PDFPast Issue PDFsSignals+ October 2021 PDF

Signals+ October 2021 PDF

October 12, 2021 Past Issue PDFs

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Previous

Douglas Philip Dyer, Ph.D.

Next

Announcing the Pfizer Junior Investigator Award Winners for Most Promising Research Presentations at the Cytokines 2021 Virtual Meeting

Member Highlights

Member Highlight: Meet Kathleen Mills

June 16, 2025

I’m a PhD candidate at Weill Cornell doing my dissertation research in Tobias Hohl’s lab at Memorial Sloan Kettering Cancer Center. My PhD work has focused on the role of GM-CSF in defense against the fungal pathogen Aspergillus fumigatus. Some of the best advice I’ve ever received is that it’s [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Photo of Amena Alrabeea in front of a waterfall
Member Highlights

Member Highlight: Meet Amenah Alrabeea, Ph.D.

June 2, 2025

My research focuses on understanding how cytokine signaling, particularly IL-6, influences disease progression and drug resistance. I’m in the process of setting up my lab at Kuwait University, where aim to study the differences between classical and trans-signaling pathways of IL-6, and how they activate cells in distinct ways. Ultimately, [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Photo of Suraj Gupta
New Member Mini-Bios

Suraj Gupta, Birla Institute of Technology and Science, Pilani – Hyderabad Campus

June 2, 2025

Mr. Suraj Gupta is a fourth-year PhD Research Scholar at the Department of Pharmacy, BITS Pilani Hyderabad Campus, India, working under the supervision of Professor Sajeli Begum. His research involves the development of novel small-molecule cytokine inhibitors. A passionate medicinal chemistry enthusiast, his journey began during his B.Pharm and M.Pharm [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Clinical Trials, contributed by Howard A. Young
Clinical Trials

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study (INCAS)

June 1, 2025

ClinicalTrials.gov ID NCT05653193 Sponsor Manchester University NHS Foundation Trust Information provided by Manchester University NHS Foundation Trust (Responsible Party) Brief Summary This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Clinical Trials, contributed by Howard A. Young
Clinical Trials

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

June 1, 2025

ClinicalTrials.gov ID NCT06130579 Sponsor Peking University People’s Hospital Information provided by Xiao-Jun Huang, Peking University People’s Hospital (Responsible Party) Brief Summary To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy

Go to mobile version